Posted by Michael Wonder on 08 Jun 2022
TLV reconsiders subsidy of cyclin-dependent kinase 4/6 inhibitor Verzenios
8 June 2022 - Since April 2022, Verzenios has had market approval for the treatment of adult patients with early breast cancer after surgery.
TLV is therefore starting a reconsideration of Verzenios to investigate whether the conditions in the Benefits Act are also met for this new area of use.
